Cannizzo S J, Frey B M, Raffi S, Moore M A, Eaton D, Suzuki M, Singh R, Mack C A, Crystal R G
Division of Pulmonary and Critical Care Medicine, New York Hospital-Cornell Medical Center, New York, USA.
Nat Biotechnol. 1997 Jun;15(6):570-3. doi: 10.1038/nbt0697-570.
This study was designed to evaluate the hypothesis that administration of a replication-deficient, recombinant adenovirus vector to the epithelial surface of the respiratory tract can be used to deliver a recombinant protein to the systemic circulation in sufficient quantities to evoke a systemic response appropriate to the recombinant protein. We administered AdCMV.TPO-an adenovirus vector containing an expression cassette coding for the human thrombopoietin (TPO) cDNA-to the respiratory epithelium of immunocompetent Balb/c mice. Over the following week, serum human TPO levels were elevated, platelet levels increased more than sixfold, and megakaryocytosis was evident in bone marrow. This strategy may be a useful approach to the nonparenteral administration of a variety of therapeutic recombinant proteins, such as those relevant to clotting, endocrine function, and bone-marrow function.
将复制缺陷型重组腺病毒载体施用于呼吸道上皮表面,可用于向体循环递送足够量的重组蛋白,以引发与该重组蛋白相适应的全身反应。我们将AdCMV.TPO(一种含有编码人血小板生成素(TPO)cDNA的表达盒的腺病毒载体)施用于具有免疫活性的Balb/c小鼠的呼吸道上皮。在接下来的一周内,血清中人TPO水平升高,血小板水平增加了六倍多,并且骨髓中出现明显的巨核细胞增多。这种策略可能是一种用于多种治疗性重组蛋白非肠道给药的有用方法,例如那些与凝血、内分泌功能和骨髓功能相关的蛋白。